An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Protocol No
JUNO-017004-TRANSCEND-CLL
Principal Investigator
Nirav Shah
Phase
I/II
Summary
Phase 1 of the study is designed to evaluate the safety of JCAR017 and to determine the best dose for treating adults with relapsed and/or refractory CLL/SLL. The information that is collected in Phase 1 will be used to select the dose that will be tested in Phase 2 of this study.
Description
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: